SYNTHETIC BIOLOGY MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

With the advent of new breakthrough technologies like Clustered regularly interspaced short palindromic repeats (CRISPR), synthetic biology is poised to revolutionize how healthcare issues are addressed. Techniques like CRISPR allow researchers to easily edit genes and regulate the expression of genetic material with unprecedented precision. This has enormous potential to treat many diseases that were previously incurable. Conditions like sickle cell anemia, cystic fibrosis, and various types of cancer which have genetic origins could potentially be corrected at the DNA level. Companies are actively pursuing therapies using genome editing for clinical applications.

CRISPR also enables the synthesis of entirely new genetic codes that do not exist in nature. Scientists are learning to programme and assemble DNA the way computers are programmed. This will allow engineering cells and biological systems with customized functions. Researchers have synthesized bacterial genomes from scratch as a proof of concept and more complex genomes will be achieved. Such advanced forms of genome engineering will drive the synthetic biology market as it opens up new paradigms for diagnosing, preventing and curing diseases. Pharmaceutical firms are investing heavily in genome editing research to develop genetically targeted treatments. As the technology matures, it will make personalized medicine a reality by allowing genetic corrections to be made for each individual's unique genetic profile.